Latest Headlines

Latest Headlines

GE Healthcare grabs genomic sequencing CRO SeqWright

GE Healthcare continues its quest to grab more genomic sequencing business, this time by snatching up contract genomic researcher SeqWright.

GE Healthcare ups molecular diagnostics game

GE Healthcare is upping its game in a bid to develop new, targeted molecular diagnostics.

Dyax enjoys climbing stock prices

Dyax had a great day Monday. The company released positive late-stage clinical trial findings regarding its drug DX-88 and investors took notice. According to its data, DX-88 reduced the symptoms

ALSO NOTED: Cross Country expands research offering; Dyax prices shares; Sciele takes stake in Addrenex; and much more...

> Cross Country Healthcare is buying Assent Consulting for $19.6 million in a deal designed to expand its biotech research services. Release

Analysts see a continuing surge of licensing deals

Merck officials would probably be among the first to agree with Needham & Associates' conclusion that the pace of biotech partnerships shows no sign of letting up. Big Pharma and Big Biotech are both avid about doing more deals to fill their pipelines. Among some of the biggest partnership deals that are likely in the works right now, they say, is a pact for Dendreon's Provenge, Dyax's …

ALSO NOTED: Intradigm completes $16M Series A financing; Prana to raise $6M to fund trial; and much more...

> Intradigm Corporation has completed a $16 million Series A financing, and has also relocated company headquarters to Palo Alto, CA from Rockville, MD. Intradigm is developing RNAi technology--a hot field which has seen a number of deals as of late. Release > Australia-based Prana Biotechnology announced that it will raise $6 million from investors to …

Jerini drug for HAE produces mixed results

Germany's Jerini is touting half of the results from two pivotal Phase III trials for Icatibant, an experimental subcutaneous treatment of hereditary angioedema (HAE). In one study, the primary endpoint was reached, showing a significant reduction in the time to onset of symptom relief. A second Phase III study, though, failed to hit its primary endpoint. The primary endpoint of median time to onset of symptom relief in the second trial was 2.5 hours for Icatibant versus 4.6 hours for …

DEALS: GSK, ChemoCentryx ink $1.5B pact

GSK, ChemoCentryx ink $1.5B pact

Dyax pockets $30M in revenue deal

Cambridge, MA-based Dyax has snared a $30 million payment from Paul Capital Partners in exchange for a portion of the revenue generated by its Phage Display Licensing and Funded Research Program. Dyax can earn another $5 million based on revenue goals covering the next two years. In late July Dyax reported widened losses for its second quarter following the termination of its collaboration with Debiopharm. "This financing structure allows Dyax to unlock the value of future …

Dyax sent back for more data on DX-88

The FDA wants Dyax to produce more data on its experimental therapy for hereditary angiodema. The drug developer said it would have to revise its timeline for FDA approval and will probably have to conduct a dose-ranging study of DX-88. Dyax and drug partner Genzyme say they are studying their options. A Phase III study is expected to wrap up soon. "The FDA wants data to ensure that the current 30 mg fixed dose of DX-88 is in fact the optimal dose for subcutaneous administration," …